Mr. Luo is responsible for running Brii’s business in China while supporting the company’s growth in the United States. He also serves as the CEO of TSB Therapeutics, a joint venture established by Brii Bio, Tsinghua University and the 3rd People’s Hospital of Shenzhen.

Mr. Luo has more than 25 years of experience in healthcare industry. Prior joining Brii, he was Vice President and General Manager of Gilead China. Mr. Luo led the development, regulatory application and launch of eight innovative products, gaining rapid access across China. He also led the team and established a unique business model encompassing science, commercialization and patient access. Prior to joining Gilead, he oversaw sales, marketing, government affairs and market access functions for leading pharmaceutical companies including Roche and Novartis. While in those positions, he led the launches of several high-profile medicines, and pioneered new patient access solutions through collaborations with private insurance companies and government agencies.

Mr. Luo received his medical education from Xiangya School of Medicine, Central-South University, serving three years as a surgeon at St. Luke’s Hospital, Shanghai. He also holds an EMBA from China Europe International Business School.